Komzifti’s U.S. launch in the final weeks of 2025 generated $2.1 million in net product revenue and unlocked a $135 million milestone payment. Kura reported an $81.0 million Q4 net loss but ended 2025 with $667.2 million in cash and expects collaboration revenue to fund its ziftomenib program through anticipated 2028 phase 3 results.

The company secured payer coverage for approximately 90% of insured lives pre-approval and 84% of private plans aligned with the label, achieving an average two-day decision via its KuraConnect platform. Analysts noted a cost advantage with a wholesale acquisition cost of just under $600,000 annually versus nearly $1 million for a competing menin inhibitor.

Komzifti is listed in the FDA Orange Book with patent exclusivity through July 2044, supporting long-term franchise value. Management highlights this intellectual property position as a cornerstone for future frontline AML expansion and combinations development.

Kura is advancing the registrational KOMET-017 program in newly diagnosed AML at roughly 200 sites, with intensive and non-intensive chemotherapy backbones designed for accelerated and full approvals. Key data readouts from KOMET-007 combination studies and additional KOMET-017 updates are expected in H1 2026 and beyond.